Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

347.86
Delayed Data
As of Jun 29
 +8.08 / +2.38%
Today’s Change
329.09
Today|||52-Week Range
605.93
-35.92%
Year-to-Date
Esperion Therapeutics Inc Sinks After FDA Says, "Ask Us in 2019"
Jun 29 / MotleyFool.com - Paid Partner Content
3 Biotech Stocks to Buy Now for the Long Haul
Jun 25 / MotleyFool.com - Paid Partner Content
Pfizer's PCSK9 Inhibitor Tops Two Additional Phase III Studies
Jun 29 / Zacks.com - Paid Partner Content
Company News for June 23, 2016
Jun 23 / Zacks.com - Paid Partner Content
Forget Stem Cell Stocks: Here Are 3 Clinical-Stage Biotechs to Buy Instead
Jun 28 / MotleyFool.com - Paid Partner Content
Warren Buffett's Favorite High-Yield Dividend Stock
Jun 22 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close339.78
Today’s open343.28
Day’s range342.42 - 351.20
Volume1,081,164
Average volume (3 months)947,437
Market cap$35.7B
Dividend yield--
Data as of 4:00pm ET, 06/29/2016

Growth & Valuation

Earnings growth (last year)+79.80%
Earnings growth (this year)-7.23%
Earnings growth (next 5 years)+20.00%
Revenue growth (last year)+45.55%
P/E ratio55.2
Price/Sales15.24
Price/Book9.73

Competitors

 Today’s
change
Today’s
% change
QQuintiles Transnatio...+1.09+1.75%
ALNYAlnylam Pharmaceutic...+0.30+0.54%
CRLCharles River Labora...+1.86+2.36%
ICLRICON PLC+2.15+3.21%
Data as of 4:02pm ET, 06/29/2016

Financials

Next reporting dateAugust 2, 2016
EPS forecast (this quarter)$2.60
Annual revenue (last year)$4.1B
Annual profit (last year)$636.1M
Net profit margin15.50%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Leonard S. Schleifer
Chief Financial Officer &
Senior VP-Finance
Robert E. Landry
Corporate headquarters
Tarrytown, New York

Forecasts

Partner Offers

Search for Jobs